Dulanermin

DB12349InvestigationalProtein Based Therapies

Dulanermin has been used in trials studying the treatment of Colorectal Cancer, Non-Hodgkin's Lymphoma, and Metastatic Colorectal Cancer.

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 10B and Tumor necrosis factor receptor superfamily member 10A
Curator reviewed
Formula / weight: C₈₇₁H₁₃₂₉N₂₄₃O₂₆₀S₄ · 19492.7851 Da
Also known as: Apo2L/TRAIL · rhApo2L/TRAIL
Code names: AMG 951 · RG 3639

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dulanermin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.